Breast Cancer Research

official impact factor 5.79

Open Access Highly Access Research article

Immunohistochemical characterization of subtypes of male breast carcinoma

Yimin Ge1, Nour Sneige2, Mahmoud A Eltorky3, Zhiqin Wang3, E Lin4, Yun Gong2 and Ming Guo2*

Author Affiliations

1 Department of Pathology, The Methodist Hospital, Weill Medical College of Cornell University, 6565 Fannin Street, Houston, Texas 77030, USA

2 Department of Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA

3 Department of Pathology, University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555, USA

4 Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA

For all author emails, please log on.

Breast Cancer Research 2009, 11:R28 doi:10.1186/bcr2258

Published: 14 May 2009

Abstract

Introduction

Male breast cancer accounts for around 1% of all breast cancer cases but the incidence has risen in recent years. This study aimed to classify the molecular subtypes of male breast cancers based on the expression profile of immunomarkers and to evaluate their association with clinicopathological features and expression patterns of epidermal growth factor receptor (EGFR) and nuclear factor κB (NF-κB).

Methods

A total of 42 cases of male breast carcinoma were examined retrospectively using immunostains for estrogen receptor (ER), progesterone receptor (PR), cytokeratin 5/6 (CK5/6), EGFR, and NF-κB. Human epidermal growth factor receptor 2 (HER2) expression was evaluated by immunostaining and confirmed by fluorescent in situ hybridization (FISH).

Results

The luminal A subtype was the most common subtype in male breast cancer (83%, 35/42), which was followed by the luminal B subtype (17%, 7/42). Basal-like and HER2+/ER- subtypes were not identified in this group. All carcinomas expressed ER and 67% of them were PR+. High nuclear grades were more common in the luminal B subtype (71%, 5/7) than in the luminal A subtype (34%, 12/35). The luminal B subtype carcinomas expressed EGFR (42%, 3/7) and NF-κB (57%, 4/7) more frequently than the luminal A subtype did (17%, 6/35 and 37%, 13/35, respectively).

Conclusions

In our study group, luminal A and B subtypes were the major subtypes of male breast carcinoma. The immunophenotypical features of male breast cancer differ from those of its female counterpart. Luminal B subtype tended to have high nuclear grade and more frequent expression of EGFR and NF-κB.